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ABSTRACT (252 words) 
Objectives 
To examine whether lamotrigine is a clinically effective and cost-effective treatment for people with 
borderline personality disorder.  
Method 
Multicentre, double-blind, placebo-controlled randomized trial.  Between July 2013 to November 
2016, we recruited 276 people aged 18 or over, who met diagnostic criteria for borderline 
personality disorder. We excluded those with co-existing bipolar affective disorder or psychosis, 
those already taking a mood stabiliser, and women at risk of pregnancy. We randomly allocated 
participants on a 1:1 ratio to up to 400mg of lamotrigine per day or an inert placebo using a remote 
web-based randomization service. The primary outcome was total score on the Zanarini Rating scale 
for Borderline Personality Disorder (ZAN-BPD) at 52 weeks. Secondary outcomes included depressive 
symptoms, deliberate self-harm, social functioning, health-related quality of life, resource use and 
costs, side effects of treatment and adverse events.  
Results 
195 (70.6%) participants were followed up at 52 weeks, at which point 49 (36%) of those prescribed 
lamotrigine and 58 (42%) of those prescribed placebo were taking it. Mean total ZAN-BPD score was 
11.3 (SD = 6.6) among those randomized to lamotrigine and 11.5 (SD = 7.7) among those randomized 
to placebo (adjusted difference in means = 0.1, 95% C.I = -1.8 to 2.0, p=0.91). There was no evidence 
of any differences in secondary outcomes. Costs of direct care for those prescribed lamotrigine were 
similar to those prescribed placebo.   
Conclusions 
Treating people with borderline personality disorder with lamotrigine is not a clinically effective or 
cost-effective use of resources.  
Trial registration 
Current Controlled Trials ISRCTN78923965. 
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Introduction 
Borderline personality disorder is a severe mental disorder that is characterised by sudden 
distressing changes in mood, unstable relationships and impulsivity (1, 2). Levels of substance misuse 
and deliberate self-harm and suicide are high among people with borderline personality disorder. 
The condition occurs globally, with a lifetime community prevalence of over 5% (3). While no drugs 
have been formally approved for the treatment of borderline personality disorder, people with this 
condition are prescribed large amounts of medication (4), with as many as 90% being prescribed 
psychiatric drugs and two-thirds taking long-term antipsychotic drugs (5-7). 
 
Rapid changes in mood are one of the hallmarks of borderline personality disorder (8). This has led 
to interest in the possibility that mood stabilisers, which improve the mental health of people with 
bipolar disorder, could also help those with borderline personality disorder (9). Current practice 
guidelines on the treatment of borderline personality disorder advocate use of mood stabilisers for 
the treatment of impulsive aggression and self-harming behaviors  (10, 11). A systematic review of 
pharmacotherapy for people with borderline personality disorder concluded that mood stabilisers 
may be effective in reducing core symptoms of the condition (12). but trials to date have been small 
and have not examined long term effects (9).  
 
Lamotrigine is an anticonvulsant that is licensed for the treatment of bipolar affective disorder. It is 
relatively safe in overdose and less teratogenic than some other mood stabilisers (13-15). Evidence 
that lamotrigine may prevent relapse in rapid-cycling bipolar disorder (16), makes it particularly 
worthy of testing among people with borderline personality disorder. Two small randomized trials 
reported reduced impulsivity and affective lability compared to an inactive placebo (17, 18). 
However both were preliminary studies which only examined short-term effects. 
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We investigated the clinical and cost-effectiveness of lamotrigine for adults with borderline 
personality disorder who were using secondary care mental health services. We followed people up 
52 weeks after randomization to examine the long-term effects of this treatment. 
 
Methods 
The LABILE (Lamotrigine And Borderline personality disorder: Investigating Long-term Effects) trial 
was a two-arm, parallel group, blinded, randomized trial of lamotrigine versus placebo for adults 
with borderline personality disorder. Full details of the trial protocol have been published elsewhere 
(19). We recruited people aged 18 or over who were in contact with mental health services in the 
United Kingdom. To take part in the study potential participants had to meet DSM-IV diagnostic 
criteria for borderline personality disorder using the Structured Clinical Interview for Axis II 
Personality Disorders (20). Potential participants were excluded if they met diagnostic criteria for 
bipolar affective disorder (type I & II) assessed using the Structured Clinical Interview for Axis I 
Disorders, or psychotic disorder (21), were prescribed a mood stabiliser currently or within the last 
four weeks, had a known history of liver or kidney impairment, or had cognitive or language 
difficulties that prevented them from providing informed consent. We also excluded any pre-
menopausal women who were breastfeeding or pregnant at the time of the baseline assessment, 
contemplating becoming pregnant during the following 12 months, or sexually active and unwilling 
to take regular contraception. Approval for the research was given by the London Central Research 
Ethics Committee (Ref: 12/LO/1514) and from the Research and Development departments of the 
participating provider organizations. The Medicines and Healthcare Products Regulatory Agency 
(MHRA) gave Clinical Trial Authorisation. 
 
Randomization and blinding 
After consenting to participate, eligible patients were asked to complete the Hypomanic Checklist 
(22), a short screening questionnaire that can distinguish those with bipolar disorder from those 
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with unipolar depression, and the International Personality Disorder Examination (IPDE) screening 
questionnaire (23), Local research staff accessed an automated randomization service operated by 
Nottingham Clinical Trials Unit that randomly allocated participants in a 1:1 ratio to either 
lamotrigine or placebo. This employed random permuted blocks of varying size, stratified by study 
centre, severity of personality disorder (using data from the IPDE and criteria developed by Tyrer 
and Johnson) (24), and extent of bipolarity (using a score of more or less than 14 on the Hypomania 
Checklist) (22).  
 
The randomization system generated a unique code for each participant corresponding to a 
predetermined active or placebo allocation. Site pharmacies were unblinded to allocation and would 
cross-reference the predetermined list held in pharmacy with each trial prescription detailing the 
participant’s randomization code, allowing selection of trial medication from the appropriate arm. 
Bottles were blinded at the point of dispensing by removal of a tear-off label which contained a code 
that identified the contents as lamotrigine or placebo in a coded format. 
 
All patients, carers and referring psychiatrists were blinded to treatment assignment until 52 weeks 
post randomization except in instances where there was an overdose, pregnancy or other adverse 
event that required disclosure.  Researchers collecting follow-up data remained blind in these 
circumstances. Blinding of researchers, trial manager and trial statistician was maintained until all 
data entry and processing were completed and the database had been locked. All study researchers, 
aside from the trial statistician and health economist, remained blind to allocation status until after 
an initial discussion of trial findings had been completed.  
 
Intervention 
All those taking part in the study continued to receive usual treatment which included contact with 
primary and secondary health services including access to psychological treatment services and 
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inpatient admission if required. No restrictions were imposed on the use of other treatments, except 
that they were not prescribed lamotrigine (aside from trial medication) or any other antiepileptic 
mood stabiliser. In addition, those randomized to the active arm of the trial were prescribed up to 
200 mg of generic lamotrigine titrated over a six week period depending on how well it was 
tolerated and clinical response. Treatment dose was titrated according to the established British 
National Formulary protocol (25) but standardised to 14-day intervals. The starting dose was 25mg 
per day. Depending on response and tolerance this was increased to 50mg after two weeks, 100mg 
after four weeks and 200mg thereafter. In keeping with recommendations, the maintenance dose 
for women taking the combined oral contraceptive pill was increased to 400mg daily (25). Those 
randomized to control treatment received usual treatment plus a prescription for an inert placebo, 
which was identical in appearance but contained lactose monohydrate. 
In the light of evidence linking adverse skin reactions with patients abruptly starting high doses of 
lamotrigine, we required participants who had a break in treatment of more than five days to re-
titrate medication from 25mg daily.  
 
Outcomes 
The primary outcome was symptoms of borderline personality disorder measured at twelve months 
using total score on the Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) (26). The 
ZAN-BPD is a widely used measure of symptoms and behavioural problems experienced by people 
with this condition. The total range of scores is 0 to 36 with higher scores indicating poorer mental 
health. The ZAN-BPD has been used in previous studies of pharmacological and psychological 
treatments for people with borderline personality disorder and is sensitive to change (27). The lead 
researcher (RS) was trained to use the ZAN-BPD and supervised all other researchers on the project. 
We examined the degree of agreement between scores on the ZAN-BPD from the pairs of 
researchers who separately rated 27 participants and found these to be highly correlated (Intraclass 
Correlation Coefficient = 0.98, 95% CI = 0.95 to 0.99). 
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The secondary outcomes were total score on the ZAN-BPD at three, six and twelve months after 
randomization, together with depression, measured using the Beck Depression Inventory (28), 
deliberate self-harm using the Acts of Deliberate Self-Harm Inventory (29), social functioning using 
the Social Functioning Questionnaire (30), use of alcohol and other drugs using the Alcohol, Smoking 
and Substance Involvement Screening Test (ASSIST) (31) and health-related quality of life using the 
EQ-5D-3L (32). Researchers assessed side effects of trial medication when interviewing participants 
using  a proforma designed to cover the possible effects listed in the British National Formulary entry 
for lamotrigine (25). Higher scores on all secondary outcomes indicate poorer health or functioning, 
aside from the EQ-5D-3L for which higher scores indicate lower health-related quality of life. Adverse 
events were also recorded. Use of health and social care resources and costs were assessed using a 
modified version of the Adult Service Use Schedule (33). This questionnaire is used to collect 
detailed data on use of all hospital and community services including medication. All secondary 
outcomes were assessed three, six, and twelve months after randomization except alcohol and drug 
use which was assessed at baseline and twelve months later.  
 
Adherence 
Researchers maintained regular contact with participants throughout the follow-up period enquiring 
about side effects and adherence every fortnight, during the initial titration phase, and then monthly 
once a maintenance dose had been reached. Participants were asked if they had missed doses of 
medication and a log was made of the dose dispensed on each occasion. We used these logs to 
record the number of weeks participants reported taking trial medication and the dose of 
medication they reported taking each week. We defined adherence with medication as the 
participant taking uninterrupted medication at a dose of 100mg or more throughout                                           
the study period after the initial titration phase had been completed. We supplemented these data 
by asking study participants to complete the Morisky Medication 4-item Adherence Scale at three, 
six and twelve months (34). This is a four item questionnaire which provides a valid estimate of 
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adherence with psychotropic medication (35). Total score ranges from 0 to 4 with higher scores 
indicating higher adherence.  
Statistical analysis 
The sample size calculation and all data analyses were conducted using Stata versions 13 and 14 
(36). In a previous trial of problem solving therapy improvements in mental health and reduced use 
of emergency medical services were seen among those who had a 3.6 point reduction in total ZAN-
BPD score.  We needed primary outcome data from 214 participants at 52 weeks to have 90% power 
to detect a minimal clinically relevant difference of 3.0 (SD = 6.75) in total score on the ZAN-BPD 
using a 0.05 two-sided level of statistical significance. To take account of 15% loss to follow-up we 
increased the target sample size to 252.  
 
Details of the statistical analyses were recorded in the Statistical Analysis Plan which was agreed by 
with the independent Trial Steering Committee prior to completion of data collection, database lock 
and unblinding of the study.  
 
The primary analysis was performed according to randomized treatment, regardless of adherence 
with allocation and without imputation of missing data. The analysis was adjusted by site, baseline 
ZAN-BPD score, severity of personality disorder (simple or complex) and the extent of bipolarity 
(score>=14 or <14). For secondary analysis of ZAN-BPD scores groups were compared using a mixed 
model for repeated outcome measures adjusted by the same stratification variables used for the 
primary analysis. We investigated whether any treatment effects were sustained or emerged later 
by including an interaction term between treatment with lamotrigine and time in the model. In the 
absence of a time effect, the effectiveness parameter was the average difference in mean ZAN-BPD 
score over the 52 week period along with 95% confidence interval and p value. Further sensitivity 
analyses were conducted to adjust for any variable with marked imbalance at baseline and 
investigate the impact of missing data, using multiple imputation.   
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We investigated the effect of treatment adherence using complier average causal effect (CACE) 
estimation methods according to whether the participant had taken trial medication at a dose of 
100mg or more without interruption during the 52 weeks prior to the final follow-up interview.  
The primary cost-effectiveness analysis involved comparing incremental differences in total costs 
and incremental differences in mental health assessed using the ZAN-BPD. In a secondary cost-utility 
analysis we compared incremental differences in costs with differences in quality of life measured 
using Quality Adjusted Life Years derived from the EQ-5D-3L. 
 
Analyses of secondary outcomes used similar methods to those in the primary analysis. We used 
general linear models for continuous outcomes and logistic regression models for binary outcomes 
and regression models with bootstrapping for cost data.  
 
For safety data including Adverse Events, Serious Adverse Events and Suspected Unexpected Serious 
Adverse Reactions we used summary statistics, i.e. number of adverse events/side effects of 
different categories, number and proportion of participants reported at least one Adverse Events or 
Serious Adverse Events within each treatment arm.  
The trial is registered with Controlled Clinical Trials as ISRCTN90916365. 
 
 
Results 
Between July 2013 and October 2015, 296 patients were screened for eligibility. Of these, 276 
(93∙2%) met eligibility criteria and were randomized (figure 1); 137 to lamotrigine plus usual care and 
139 to placebo plus usual care. There were no instances in which researchers were unblinded to the 
participants’ allocation status prior to completion of collection of 52 week outcome data. 
Baseline demographic and clinical characteristics of study groups were comparable (table 1).  Follow 
up rates were similar between treatment arms with 195 (71%) participants completing the 52 week 
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follow up (fig. 1). In total 93 (33.7%) participants took trial medication as per protocol and similar 
proportions were seen in both arms (table 2). At 12 weeks, 68.8% were taking trial medication 
regularly, with 38.9% taking it regularly at 12 months. 
 
There was a decrease in ZAN-BPD at 12 weeks, after which it remained stable throughout the 
remainder of the follow up. Total scores on ZAN-BPD in the lamotrigine arm of the trial were 11.5 at 
12 weeks, 11.9 at 24 weeks and 11.3 at 52 weeks. Corresponding scores among those in the control 
arm of the trial were 11.5, 11.9 and 11.5 (see figure 2).  No difference was found in total ZAN-BPD 
score at 52 weeks between treatment arms. No difference was found in any of the secondary 
outcomes, nor in the four sub scores of the ZAN-BPD at any time point (table 3 and supplementary 
tables S1-S4). The lack of treatment effect was supported by sensitivity analyses. Adjusted difference 
in mean ZAN-BPD was 0.0 (95% CI = -1.25 to 1.26, p = 0.90) using repeated measures, -0·1 (95% CI = -
1.9 to 1.8) using multiple imputation for missing data and 0.3 (95% CI = -3.7 to 4.3) when adjusted 
for adherence. Regarding adverse events, 77 (56%) of those in the lamotrigine arm of the trial had 
one or more event, compared to 93 (67%) of those in the control arm of the trial (table 4). The 
corresponding figures for serious adverse events were 26 (19%) in the active arm of the trial and 32 
(23%) in the control arm, including five pregnancies (three in the lamotrigine group and two in the 
control group).  
 
At baseline, costs were on average $8,160 in the lamotrigine group and $5,163 in the placebo group 
in the six months prior to randomization. Average total costs over 52 weeks were $17,785 in the 
lamotrigine group and $12,340  in the control arm of the trial. The difference in cost was not 
statistically significant (adjusted difference = $931.99, 95% CI = -2,740.44 to 4,604.41, p=0.62). 
Group differences between health-related quality of life and the resulting Quality Adjusted Life Years 
were also not statistically significant. 
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Discussion 
In this placebo-controlled randomized trial, we found no evidence that prescribing lamotrigine to 
people with borderline personality disorder led to improvements in their mental health. The study 
was large enough to generate a precise estimate of the overall treatment effect, which did not 
include the minimum clinically important difference of 3.0 on the ZAN-BPD at 12 months (the 
primary outcome measure). Levels of adherence to trial medication were low with only a third (n = 
93, 33.7%) of study participants taking trial medication throughout as specified in the study protocol. 
Levels of adherence were higher during the first 12 weeks of the study when two-thirds of 
participants were taking the medication (n = 190, 68.8%), but we did not find differences in study 
outcomes during this period.  In a secondary analysis using Complier Average Causal Effect methods 
we found no evidence that greater adherence to trial medication was associated with any benefit to 
patients. Most participants reported one or more adverse effects, but those in the lamotrigine arm 
of the trial were no more likely to report potential side effects than those in the placebo arm of the 
trial.  
 
Strengths and limitations of the study  
The LABILE trial is the first ever phase III trial of a mood stabiliser for people with borderline 
personality disorder. One of the main strengths of the study is that we followed participants up over 
a 12 month period. Borderline personality disorder is a long-term condition but previous drug trials 
have not examined long-term outcomes (12). We recruited 11% more participants than we originally 
planned and the study size allowed precision to exclude a minimum clinically significant difference in 
the severity of symptoms of borderline personality disorder.  
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In this pragmatic trial we attempted to replicate clinical practice. However one area where we were 
unable to do this was in the means by which participants obtained their medication. Rather than 
collecting medication from a local pharmacy most participants had medication delivered to them in 
person or by post. This meant that participants had more regular contact with staff than they would 
have done in normal clinical practice. While levels of adherence to medication were low in this trial 
we believe that the additional contact that participants had with researchers meant that they may 
have been higher than would be seen in routine clinical practice. 
 
Comparison with results of previous trials 
In contrast to the results of the LABILE study, the two previous randomized trials of lamotrigine for 
people with borderline personality disorder both reported positive effects (17, 18). Both trials were 
smaller, had a larger number of exclusion criteria and followed participants up for a shorter period 
of time. Several factors may explain differences in the results of the LABILE study and the two 
previous studies. Randomization does not guarantee that treatment arms are balanced in small trials 
and it is possible that differences in study outcomes in these previous trials resulted from 
differences in baseline characteristics of the samples. Secondly, in this pragmatic trial we 
deliberately kept our exclusion criteria to a minimum. This approach meant that were able to recruit 
people with the type of complex and severe problems that people with borderline personality 
disorder who use speciality mental health services generally have. It is possible that lamotrigine 
reduces symptoms of borderline personality disorder among people who have less complex and 
severe mental health problems than we recruited to the study. In the LABILE trial we had a rigorous 
process for maintaining blinding through the use of an automated web-based system that allocated 
study participants.  Methods used to maintain blinding in previous trials are unclear (17). 
 
Implications for clinicians  
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At present most people with borderline personality disorder who are in contact with mental health 
services are being prescribed psychiatric drugs (7); with a quarter being prescribed unlicensed mood 
stabilisers  (5). Use of lamotrigine is specifically recommended in some textbooks on the treatment 
of people with borderline personality disorder (11). Clinicians may feel under considerable pressure 
to prescribe medication for people with borderline personality disorder especially at times of crisis  
(6). In the absence of clear evidence suggesting benefits associated with any type of medication, 
non-pharmacological approaches should be offered (2, 9).  
 
Reductions in symptoms of borderline personality disorder during the course of the trial are in 
keeping with the results of longitudinal studies showing that the mental health of people with this 
condition improves over time (37, 38). However the pattern of improvement among study 
participants, with reductions in symptoms during the first 12 weeks of the trial, suggests that 
regression to the mean or general factors such as instillation of hope may have been responsible for 
this improvement.   
 
In the LABILE trial we took great care not to recruit women who were pregnant, wanting to become 
pregnant or were pre-menopausal, sexually active and unwilling to take regular contraception. 
Despite the assurances that participants gave us, five subsequently became pregnant during the 
trial. While lamotrigine has been shown to be relatively safe in pregnancy, this is not true of all mood 
stabilisers – notably sodium valproate (39). Warnings have been issued about the use of off-licence 
sodium valproate to women of child bearing age (40). Despite this a recent national audit showed 
that over 10% of women with borderline personality disorder who are in contact with secondary 
care mental health services in the UK are currently being prescribed this drug (5). Data from the 
LABILE trial emphasises the importance of avoiding use of unlicensed medications that are 
potentially teratogenic for women with borderline personality disorder who are of child bearing age. 
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Conclusions 
Based on the results of this trial we do not recommend that people with borderline personality 
disorder are prescribed lamotrigine. While pharmacological treatment of coexisting mental health 
conditions is important, we did not find evidence to support the use of lamotrigine for treatment the 
core symptoms of borderline personality disorder.  
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Figure 1 CONSORT diagram 
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Randomised (n = 276) 
 
Allocated to lamotrigine (n = 137) 
 
Allocated to placebo (n = 139)  
 
Primary outcome not available    
(n = 40) 
Consent withdrawn (n = 14) 
Lost to follow up (n = 16) 
Deaths (n = 0) 
Adverse event (n = 4) 
Other (n = 6) 
 
41 primary outcome not available 
(n = 41) 
Consent withdrawn (n = 12)  
Lost to follow up (n = 20) 
Deaths (n = 30) 
Adverse event (n = 1) 
Other (n = 5) 
 
Included in primary analysis (n = 97) 
 
Included in primary analysis (n = 98) 
 
 
Not randomised (n = 20) 
 Withdrew prior to 
randomisation (n = 7) 
 Ineligible (n = 11) 
 Not contactable (n = 2) 
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Table 1: Summary characteristics of study participants by intervention group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ZAN-BPD - Zanarini rating scale for Borderline Personality Disorder 
SD = Standard deviation 
*Missing data: n = 137 lamotrigine and 134 placebo 
# Missing data: n = 72 lamotrigine and 75 placebo 
 
 
 
 
 
 
Characteristic   Lamotrigine         Placebo 
N/ 
mean 
%/ SD N/ 
mean 
%/ SD 
Mean age in years at randomization (SD) 
 
36.0 11 36.2 11 
Gender:                          Male 34 25 34 24 
                                         Female 
 
103  75 105 76 
Ethnicity:                        White 123 90 123 90 
                                         Black 7 5 4 3 
                                         Asian 1 1 2 1 
                                         Other 
 
6 4 10 7 
Employment status*:  Employed  34 25 26 19 
                                         Unemployed 95 69 105 76 
                                         Student 4 3 1 1 
                                         Retired 
 
2 1 2 1 
Severity of personality disorder: Simple 0 0 2 1 
                                                           Complex 
 
137 100 137 99 
ZAN-BPD* (mean, SD) 
 
16.6 5.8 17.4 6.2 
Beck Depression Inventory* (mean, SD) 
 
39.8 11.7 38.4 10.2 
Deliberate self-harm in previous six months 
 
96 70 51 37 
Current alcohol misuse: yes 
 
53 39 54 39 
Current drug misuse: yes 
 
54 39 47 34 
Social functioning score* (mean) 
 
15.0 4.1 14.9 4.5 
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Table 2: Adherence to trial medication 
 
    Lamotrigine 
 
Placebo  
 
 
 N/ mean %/ IQR N/ mean %/IQR 
     
Study medication received per protocol* 44  32 49  35 
     
Morisky Rating scale at 12 month#  
Median [IQR] 3 
 
2,4 3  
 
2,4 
     
Number of weeks participants received 
study medication Median [IQR]  32 
 
9, 52 46 
 
7,52 
     
Number receiving medication throughout 
first 12 weeks 
95 
 
69 95  
 
68 
     
Number receiving medication 40 to 52 
weeks 49  
 
36 58  
 
42 
     
Dose of medication at 12 weeks in mg 
Median [IQR] 200 
 
200, 200 200 
 
200, 200 
     
Dose of medication at 52 weeks in mg 
Median [IQR] 200 
 
200,200 200 
 
200,200 
     
IQR = Inter quartile range 
*Following initial titration participant stayed on a dose of 100mg or more throughout                                           
the remainder of the study 
# Missing data: n = 88 lamotrigine and 82 placebo 
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Figure 2. Change in total ZAN-BPD score at 12, 26 and 52 weeks. 
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Table 3: Primary and secondary outcomes at 52 weeks  
 
*Adjusted by site and other stratification factors. Estimate is difference in means for continuous outcomes, and odds ratio for binary outcomes. Severity 
was not included in the model for self-harm, alcohol use and any other substance use due to collinearity.  
Summary statistics is mean [SD] for continuous outcomes and N (%) for binary outcomes.  
*Missing data: n = 83 lamotrigine and 77 placebo
 
    Lamotrigine 
N/ mean  
 
%/ SD 
      Placebo 
N/ mean  
 
%/ SD 
*Adjusted 
difference  
95% Confidence 
Intervals 
p-value 
Zanarini Scale for Borderline Personality 
Disorder 
11.3  6.6 11.5 7.7 0.1 -1.8, 2.0 0.906 
Beck Depression Inventory [SD] 28.8 16.1 28.7 15.5 -0.2 -4.5,4.1 0.937 
Deliberate self-harm in last 6m (n, %)  45  46 8 39 1.25 0.68, 2.28 0.464 
Social Functioning Questionnaire 12.4 4.3 12.3 4.9 0 -1.2, 1.2 0.987 
Alcohol use# 28 31 22 25 1.4 0.7, 2.7 0.354 
Any other drug  use#   27 30 23 26 1.2 0.6, 2.3 0.598 
        
Total cost 12244.3 17442.8 8495.4 11349.1 641.6 -1886.6, 3169.8 0.617 
Quality Adjusted Life Years 0.467 0.300 0.511 0.269 -0.012 -0.057, 0.034 0.612 
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Table 4: Summary of adverse events among study participants by intervention group by Medical 
Dictionary for Regulatory Activities (MedDRA) classifications 
 
 Lamotrigine 
  
Placebo 
 
Total number of adverse events 246 285  
Total number of participants with at least one adverse event 77 93 
Total number of adverse events by system organ class  
Blood and lymphatic system disorders 2 3 
Cardiac disorders 0 1 
Endocrine disorders 0 1 
Eye disorders 1 6 
Gastrointestinal disorders 38 55 
General disorders and administration site conditions 14 14 
Hepatobiliary disorders 1 0 
Immune system disorders 1 1 
Infections and infestations 23 38 
Injury, poisoning and procedural complications 17 39 
Investigations 7 3 
Metabolism and nutrition disorders 2 1 
Musculoskeletal and connective tissue disorders 8 7 
Nervous system disorders 32 31 
Pregnancy, puerperium and perinatal conditions 3 2 
Psychiatric disorders 37 40 
Renal and urinary disorders 1 0 
Reproductive system and breast disorders 3 1 
Respiratory, thoracic and mediastinal disorders 16 9 
Skin and subcutaneous tissue disorders 35 31 
Social circumstances 1 1 
Surgical and medical procedures 4 1 
   
 
